LifeStance Health Group (NASDAQ:LFST) Shares Gap Up – Still a Buy?

LifeStance Health Group, Inc. (NASDAQ:LFST) gapped up prior to trading on Wednesday . The stock had previously closed at $7.14, but opened at $7.99. LifeStance Health Group shares last traded at $7.5950, with a volume of 1,438,441 shares.

Analysts Set New Price Targets

Several research analysts have recently commented on LFST shares. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. UBS Group upped their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Barclays assumed coverage on LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price target on the stock. Finally, Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

LifeStance Health Group Stock Up 3.7%

The firm has a market cap of $2.88 billion, a PE ratio of -247.83 and a beta of 1.12. The company’s 50-day simple moving average is $7.11 and its two-hundred day simple moving average is $6.17. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58.

Insider Buying and Selling

In other news, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the transaction, the director directly owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the sale, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 270,086 shares of company stock worth $1,891,264. Corporate insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC lifted its holdings in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the last quarter. Bayesian Capital Management LP purchased a new position in LifeStance Health Group during the second quarter valued at $52,000. Krane Funds Advisors LLC bought a new stake in LifeStance Health Group in the fourth quarter worth $71,000. Cibc World Markets Corp purchased a new stake in shares of LifeStance Health Group in the fourth quarter worth $77,000. Finally, Qtron Investments LLC bought a new position in shares of LifeStance Health Group during the fourth quarter valued at $83,000. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.